Drug Resistance in NIH3T3 Cells with c-myc and c-H-ras Genes
Author Information
Author(s): S. Niimi, K. Nakagawa, J. Yokota, Y. Tsunokawa, K. Nishio, Y. Terashima, M. Shibuya, M. Terada, N. Saijo
Primary Institution: National Cancer Center Research Institute
Hypothesis
Does the expression of c-myc and c-H-ras oncogenes affect drug resistance in NIH3T3 cells?
Conclusion
The study found that the c-myc gene increases resistance to several anticancer drugs, while c-H-ras primarily affects resistance to alkylating agents.
Supporting Evidence
- Transfection with c-myc led to higher IC50 values for multiple anticancer drugs.
- c-H-ras transfection increased resistance to alkylating agents but not to cisplatin.
- NIH3T3 cells with c-myc showed significant resistance compared to parental cells.
Takeaway
Some cancer cells can become resistant to medicine, and this study shows that a specific gene called c-myc makes these cells tougher against certain drugs.
Methodology
NIH3T3 cells were transfected with c-myc and/or c-H-ras genes, and their drug sensitivity was tested using the MTT assay.
Limitations
The study does not explore the exact mechanisms by which c-myc increases drug resistance.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website